Turn Therapeutics (NASDAQ:TTRX) Stock Rating Raised to “Hold” at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at WBB Securities from a “sell” rating to a “hold” rating in a research note issued on Friday, MarketBeat reports. The brokerage currently has a $10.00 price target on the stock. WBB Securities‘s price objective indicates a potential downside of 4.41% from the stock’s current price.

A number of other research firms have also weighed in on TTRX. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Wall Street Zen lowered Turn Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 18th. Finally, Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Turn Therapeutics Trading Up 2.8%

Shares of TTRX opened at $10.46 on Friday. The stock’s 50-day moving average is $11.63 and its two-hundred day moving average is $8.13. The stock has a market cap of $319.37 million and a PE ratio of -35.61. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities analysts forecast that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Trading of Turn Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ieq Capital LLC purchased a new position in Turn Therapeutics in the 2nd quarter worth about $1,660,000. Bridgewater Advisors Inc. purchased a new position in Turn Therapeutics in the 2nd quarter worth about $242,000. DDFG Inc increased its stake in Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after purchasing an additional 18,246 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Turn Therapeutics in the 2nd quarter worth about $119,000. Finally, BlackRock Inc. purchased a new position in Turn Therapeutics in the 2nd quarter worth about $282,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.